Literature DB >> 7430635

Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.

S Sone, I J Fidler.   

Abstract

Alveolar macrophages (AM) from lungs of normal F344 rats can be rendered tumoricidal by incubation in vitro with either muramyl dipeptide (MDP) at a minimum dose of 10 micrograms/ml or undiluted cell-free culture supernatants from mitogen-stimulated F344 rat lymphocytes rich in macrophage-activating factor (MAF) activity. Neither MAF at dilutions exceeding 1:6 nor MDP at doses lower than 10 micrograms/ml activated AM to become tumor cytotoxic. The combination of agents at subthreshold amounts (MAF 1:18; MDP 0.001 to 1 microgram/ml) activated AM to significant levels of cytotoxicity. AM activated by these agents were rendered tumoricidal and destroyed syngeneic, allogeneic, and xenogeneic tumor targets in vitro. The synergism for AM activation between preparations of MAF and MDP required that AM be incubated first with MAF and then with MDP. Even a 15-min treatment of AM with MAF conditioned the cells to respond to subthreshold amounts of MDP and to be rendered tumoricidal. Since treatment of MAF and MDP with polymyxin B did not interfere with macrophage activation, we were able to rule out the possibility that our preparations were contaminated with lipopolysaccharide. Synergism for AM activation was demonstrated also when AM were treated with MAF and MDP encapsulated within liposomes. This finding suggests that the binding of agents to the macrophage surface is not a prerequisite for the synergistic activation of AM by MAP and MDP.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7430635

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections.

Authors:  J Drews
Journal:  Infection       Date:  1985       Impact factor: 3.553

2.  Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs.

Authors:  R J Ho; R L Burke; T C Merigan
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

3.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Activation of antitumor properties in alveolar macrophages from protein-calorie malnourished rats.

Authors:  S Mutsuura; S Sone; E Tsubura; K Tachibana; Y Kishino
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Immunostimulation. Clinical and experimental perspectives.

Authors:  J Drews
Journal:  Klin Wochenschr       Date:  1984-03-15

6.  The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections.

Authors:  J Drews
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

7.  A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.

Authors:  S Sone; T Utsugi; P Tandon; M Ogawara
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Stimulation of migration of human monocytes by bacterial cell walls and muramyl peptides.

Authors:  T Ogawa; S Kotani; K Fukuda; Y Tsukamoto; M Mori; S Kusumoto; T Shiba
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

9.  Synergism of synthetic acyltripeptide and its analogs with recombinant interferon gamma for activation of antitumor properties of human blood monocytes.

Authors:  S Sone; A Okubo; N Inamura; A Nii; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models.

Authors:  B P Barna; D A Eppstein; M J Thomassen; J J Nestor; T Ho; S V Medendorp; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.